HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (3,4- dimethoxyphenyl)- 1- (5- methoxy- 2,2- dimethyl- 2H- chromen- 6- yl)ethanone

an Hsp90 inhibitor; structure in first source

Also Known As:

SH-1242

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethanone: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethanone: 3

Experts

1.	Suh, Young-Ger: 3 articles (01/2020 - 10/2014)
2.	Lee, Seungbeom: 2 articles (01/2020 - 02/2016)
3.	An, Hongchan: 2 articles (02/2016 - 10/2014)
4.	Kim, Kyu-Won: 2 articles (02/2016 - 10/2014)
5.	Kim, Young-Myeong: 2 articles (02/2016 - 10/2014)
6.	Lee, Ho-Young: 2 articles (02/2016 - 10/2014)
7.	Lee, Jeewoo: 2 articles (02/2016 - 10/2014)
8.	Park, Hyun-Ju: 2 articles (02/2016 - 10/2014)
9.	Park, So-Jung: 2 articles (02/2016 - 10/2014)
10.	Baek, Minjeong: 1 article (01/2020)

Related Diseases

1.	Retinal Neovascularization 10/01/2014 - "Hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1α destabilization by SH-1242 and SH-1280, novel hsp90 inhibitors." 10/01/2014 - "In this study, we demonstrate that destabilization of hypoxia-inducible factor-1α (HIF-1α) by SH-1242 and SH-1280, novel heat shock protein 90 (hsp90) inhibitors, leads to suppression of hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina. " 01/25/2020 - "SH-1242, a novel inhibitor of heat shock protein 90 (HSP90), is a synthetic analog of deguelin: It was previously reported that the treatment of SH-1242 led to a strong suppression of hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retinas by inhibiting the hypoxia-induced upregulation of expression in hypoxia-inducible factor 1α (HIF-1ɑ) and vascular endothelial growth factor (VEGF). "
2.	Hypoxia (Hypoxemia) 10/01/2014 - "Hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1α destabilization by SH-1242 and SH-1280, novel hsp90 inhibitors." 10/01/2014 - "In this study, we demonstrate that destabilization of hypoxia-inducible factor-1α (HIF-1α) by SH-1242 and SH-1280, novel heat shock protein 90 (hsp90) inhibitors, leads to suppression of hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina. " 01/25/2020 - "SH-1242, a novel inhibitor of heat shock protein 90 (HSP90), is a synthetic analog of deguelin: It was previously reported that the treatment of SH-1242 led to a strong suppression of hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retinas by inhibiting the hypoxia-induced upregulation of expression in hypoxia-inducible factor 1α (HIF-1ɑ) and vascular endothelial growth factor (VEGF). "
3.	Lung Neoplasms (Lung Cancer) 02/01/2016 - "In a KRAS-driven mouse model of lung cancer, SH-1242 administration reduced tumor multiplicity, volume, and load. " 02/01/2016 - "In this study, we report progress on deguelin analogues that address this limitation, focusing on the novel analogue SH-1242 as a candidate to broadly target human lung cancer cells, including those that are chemoresistant or harboring KRAS mutations. "
4.	Neoplasms (Cancer) 02/01/2016 - "Similarly, in human cell line-based or patient-derived tumor xenograft models, SH-1242 induced apoptosis and reduced tumor vasculature in the absence of detectable toxicity. " 02/01/2016 - "In a KRAS-driven mouse model of lung cancer, SH-1242 administration reduced tumor multiplicity, volume, and load. "

Related Drugs and Biologics

1.	Heat-Shock Proteins (Heat-Shock Protein)
2.	deguelin
3.	(S)- 2- (3,4- dimethoxyphenyl)- 1- (5- methoxy- 2,2- dimethyl- 2H- chromen- 6- yl)propan- 1- one
4.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)